2023 World Conference on Lung Cancer (Posters)-EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens

EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens - PDF(Slides)

Back to course

Pdf Summary

This study compares the clinicopathological features and postoperative prognosis of two types of lung cancer: large-cell neuroendocrine carcinoma (LCNEC) and large-cell lung carcinoma (LCLC). LCNEC was once classified as a subtype of LCLC but is now considered a high-grade neuroendocrine carcinoma. The study aims to address the difficulty in diagnosing LCNEC and LCLC and the confusion that can arise for clinicians.<br /><br />The study included 81 patients who underwent radical resection of lung cancer, with 40 cases of LCLC and 41 cases of LCNEC. The baseline characteristics of the two groups were similar. The median disease-free survival (DFS) of the LCLC group was 19.47 months, while the median DFS of the LCNEC group was estimated to be 29.40 months. The recurrence or metastasis rate was high within 5 months after surgery for both groups. The proportion of increased serum CYFRA21-1, a tumor marker, was higher in the LCLC group compared to the LCNEC group. The proportion of tumor mass necrosis was slightly higher in the LCLC group. Adjuvant chemotherapy regimens differed between the two groups but did not significantly affect DFS.<br /><br />Factors affecting DFS differed between the two groups. Visceral pleural invasion, central type, and left lung location were significant risk factors for DFS in the LCLC group. In contrast, the maximum tumor diameter, elevated serum NSE (a neuroendocrine tumor marker), and right lung location were significant risk factors in the LCNEC group.<br /><br />In conclusion, LCNEC and LCLC have similar clinicopathological features. Early recurrence or metastasis rates were high in both types of cancer. The increase in CYFRA21-1 levels can help distinguish between LCNEC and LCLC. Different factors influenced DFS in each group, but the effect of different adjuvant chemotherapy regimens on DFS was not significant.

Asset Subtitle

Junxi Xu

Meta Tag

Speaker Junxi Xu

Topic SCLC & Neuroendocrine Tumors: NETs

Keywords

lung cancer

LCNEC

LCLC

clinicopathological features

postoperative prognosis

diagnosis

recurrence

metastasis

tumor marker

adjuvant chemotherapy